Neutralizing antibodies to HIV-1 induced by immunization

Journal of Experimental Medicine

Volumn 210, Issue 2, 2013, Pages 209-223

  McCoy, Laura E ^a   Weiss, Robin A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; CELL CLONING; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; SUPERNATANT; TREATMENT FAILURE;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR;

EID: 84874561170     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20121827     Document Type: Review

References (169)

1. Abdool Karim, Q., S.S. Abdool Karim, J.A. Frohlich, A.C. Grobler, C. Baxter, L.E. Mansoor, A.B. Kharsany, S. Sibeko, K.P. Mlisana, Z. Omar, et al; CAPRISA 004 Trial Group. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 329:1168-1174. http://dx.doi.org/10.1126/science.1193748
2. Ahmed, F.K., B.E. Clark, D.R. Burton, R. Pantophlet. 2012. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine. 30:922-930. http://dx.doi.org/10.1016/j.vaccine.2011.11.089
3. Alam, S.M., M. Morelli, S.M. Dennison, H.X. Liao, R. Zhang, S.M. Xia, S. Rits-Volloch, L. Sun, S.C. Harrison, B.F. Haynes, B. Chen. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA. 106:20234-20239. http://dx.doi.org/10.1073/pnas.0908713106
4. Andrus, L., A.M. Prince, I. Bernal, P. McCormack, D.H. Lee, M.K. Gorny, S. Zolla-Pazner. 1998. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J. Infect. Dis. 177:889- 897. http://dx.doi.org/10.1086/515251
5. Arnold, G.F., P.K. Velasco, A.K. Holmes, T. Wrin, S.C. Geisler, P. Phung, Y. Tian, D.A. Resnick, X. Ma, T.M. Mariano, et al. 2009. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J. Virol. 83:5087-5100. http://dx.doi.org/10.1128/JVI.00184-09
6. Balazs, A.B., J. Chen, C.M. Hong, D.S. Rao, L. Yang, D. Baltimore. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 481:81-84. http://dx.doi.org/10
7. Barbato, G., E. Bianchi, P. Ingallinella, W.H. Hurni, M.D. Miller, G. Ciliberto, R. Cortese, R. Bazzo, J.W. Shiver, A. Pessi. 2003. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J. Mol. Biol. 330:1101-1115. http://dx.doi.org/10.1016/S0022-2836(03)00611-9
8. Barnett, S.W., S. Rajasekar, H. Legg, B. Doe, D.H. Fuller, J.R. Haynes, C.M. Walker, K.S. Steimer. 1997. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine. 15:869-873. http://dx.doi.org/10.1016/S0264-410X(96)00264-2
9. Barnett, S.W., S. Lu, I. Srivastava, S. Cherpelis, A. Gettie, J. Blanchard, S. Wang, I. Mboudjeka, L. Leung, Y. Lian, et al. 2001. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75:5526-5540. http://dx.doi.org/10.1128/JVI.75.12.5526-5540.2001
10. Barnett, S.W., I.K. Srivastava, E. Kan, F. Zhou, A. Goodsell, A.D. Cristillo, M.G. Ferrai, D.E. Weiss, N.L. Letvin, D. Montefiori, et al. 2008. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS. 22:339-348. http://dx.doi.org/10.1097/QAD.0b013e3282f3ca57
11. Barnett, S.W., B. Burke, Y. Sun, E. Kan, H. Legg, Y. Lian, K. Bost, F. Zhou, A. Goodsell, J. Zur Megede, et al. 2010. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 84:5975-5985. http://dx.doi.org/10.1128/JVI.02533-09
12. Barouch, D.H. 2010. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS. 5:386-390. http://dx.doi.org/10.1097/COH.0b013e32833cfe4c
13. Barouch, D.H., J. Liu, H. Li, L.F. Maxfield, P. Abbink, D.M. Lynch, M.J. Iampietro, A. SanMiguel, M.S. Seaman, G. Ferrari, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 482:89-93. http://dx.doi.org/10.1038/nature10766
14. Bartlett, J.A., S.S. Wasserman, C.B. Hicks, R.T. Dodge, K.J. Weinhold, C.O. Tacket, N. Ketter, A.E. Wittek, T.J. Palker, B.F. Haynes Division of AIDS Treatment Research Initiative. 1998. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. AIDS. 12:1291-1300. http://dx.doi.org/10.1097/00002030-199811000-00010
15. Beddows, S., M. Franti, A.K. Dey, M. Kirschner, S.P. Iyer, D.C. Fisch, T. Ketas, E. Yuste, R.C. Desrosiers, P.J. Klasse, et al. 2007. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology. 360:329-340. http://dx.doi.org/10.1016/j.virol.2006.10.032
16. Beirnaert, E., P. Nyambi, B. Willems, L. Heyndrickx, R. Colebunders, W. Janssens, G. van der Groen. 2000. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J. Med. Virol. 62:14-24. http://dx.doi.org/10.1002/1096-9071(200009)62:1<14::AID-JMV3>3.0.CO;2-L
17. Bell, C.H., R. Pantophlet, A. Schiefner, L.A. Cavacini, R.L. Stanfield, D.R. Burton, I.A. Wilson. 2008. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J. Mol. Biol. 375:969-978. http://dx.doi.org/10.1016/j.jmb.2007.11.013
18. Belshe, R.B., G.J. Gorse, M.J. Mulligan, T.G. Evans, M.C. Keefer, J.L. Excler, A.M. Duliege, J. Tartaglia, W.I. Cox, J. McNamara, et al; NIAID AIDS Vaccine Evaluation Group. 1998. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS. 12:2407-2415. http://dx.doi.org/10.1097/00002030-199818000-00009
19. Berman, P.W., J.E. Groopman, T. Gregory, P.R. Clapham, R.A. Weiss, R. Ferriani, L. Riddle, C. Shimasaki, C. Lucas, L.A. Lasky, et al. 1988. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA. 85:5200-5204. http://dx.doi.org/10.1073/pnas.85.14.5200
20. Berman, P.W., T.J. Gregory, L. Riddle, G.R. Nakamura, M.A. Champe, J.P. Porter, F.M. Wurm, R.D. Hershberg, E.K. Cobb, J.W. Eichberg. 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 345:622- 625. http://dx.doi.org/10.1038/345622a0
21. Binley, J.M., T. Wrin, B. Korber, M.B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252. http://dx.doi.org/10.1128/JVI.78.23.13232-13252.2004
22. Binley, J.M., E.A. Lybarger, E.T. Crooks, M.S. Seaman, E. Gray, K.L. Davis, J.M. Decker, D. Wycuff, L. Harris, N. Hawkins, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668. http://dx.doi.org/10.1128/JVI.01762-08
23. Bogers, W.M., D. Davis, I. Baak, E. Kan, S. Hofman, Y. Sun, D. Mortier, Y. Lian, H. Oostermeijer, Z. Fagrouch, et al. 2008. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology. 382:217-225. http://dx.doi.org/10.1016/j.virol.2008.09.016
24. Bomsel, M., M. Heyman, H. Hocini, S. Lagaye, L. Belec, C. Dupont, C. Desgranges. 1998. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity. 9:277-287. http://dx.doi.org/10.1016/S1074-7613(00)80610-X
25. Bonsignori, M., D.C. Montefiori, X. Wu, X. Chen, K.K. Hwang, C.Y. Tsao, D.M. Kozink, R.J. Parks, G.D. Tomaras, J.A. Crump, et al. 2012. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 86:4688-4692. http://dx.doi.org/10.1128/JVI.07163-11
26. Bower, J.F., X. Yang, J. Sodroski, T.M. Ross. 2004. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J. Virol. 78:4710-4719. http://dx.doi.org/10.1128/JVI.78.9.4710-4719.2004
27. Burke, B., S.W. Barnett. 2007. Broadening our view of protective antibody responses against HIV. Curr. HIV Res. 5:625-641. http://dx.doi.org/10.2174/157016207782418533
28. Burton, D.R., R.A. Weiss. 2010. AIDS/HIV. A boost for HIV vaccine design. Science. 329:770-773. http://dx.doi.org/10.1126/science.1194693
29. Burton, D.R., J. Pyati, R. Koduri, S.J. Sharp, G.B. Thornton, P.W. Parren, L.S. Sawyer, R.M. Hendry, N. Dunlop, P.L. Nara, et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1024-1027. http://dx.doi.org/10.1126/science.7973652
30. Burton, D.R., P. Poignard, R.L. Stanfield, I.A. Wilson. 2012. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 337:183-186. http://dx.doi.org/10.1126/science.1225416
31. Calarese, D.A., C.N. Scanlan, M.B. Zwick, S. Deechongkit, Y. Mimura, R. Kunert, P. Zhu, M.R. Wormald, R.L. Stanfield, K.H. Roux, et al. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 300:2065-2071. http://dx.doi.org/10.1126/science.1083182
32. Chaillon, A., M. Braibant, T. Moreau, S. Thenin, A. Moreau, B. Autran, F. Barin. 2011. The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. J. Virol. 85:3642-3648. http://dx.doi.org/10.1128/JVI.02424-10
33. Chakrabarti, B.K., W.P. Kong, B.Y. Wu, Z.Y. Yang, J. Friborg, X. Ling, S.R. King, D.C. Montefiori, G.J. Nabel. 2002. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76:5357-5368. http://dx.doi.org/10.1128/JVI.76.11.5357-5368.2002
34. Chakrabarti, B.K., X. Ling, Z.Y. Yang, D.C. Montefiori, A. Panet, W.P. Kong, B. Welcher, M.K. Louder, J.R. Mascola, G.J. Nabel. 2005. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine. 23:3434-3445. http://dx.doi.org/10.1016/j.vaccine.2005.01.099
35. Connor, R.I., B.T. Korber, B.S. Graham, B.H. Hahn, D.D. Ho, B.D. Walker, A.U. Neumann, S.H. Vermund, J. Mestecky, S. Jackson, et al. 1998. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72:1552-1576.
36. Corti, D., J.P. Langedijk, A. Hinz, M.S. Seaman, F. Vanzetta, B.M. Fernandez-Rodriguez, C. Silacci, D. Pinna, D. Jarrossay, S. Balla-Jhagjhoorsingh, et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE. 5:e8805. http://dx.doi.org/10.1371/journal.pone.0008805
37. Deeks, S.G., B. Schweighardt, T. Wrin, J. Galovich, R. Hoh, E. Sinclair, P. Hunt, J.M. McCune, J.N. Martin, C.J. Petropoulos, F.M. Hecht. 2006. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J. Virol. 80:6155-6164. http://dx.doi.org/10.1128/JVI.00093-06
38. Dennison, S.M., L.L. Sutherland, F.H. Jaeger, K.M. Anasti, R. Parks, S. Stewart, C. Bowman, S.M. Xia, R. Zhang, X. Shen, et al. 2011. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS ONE. 6:e27824. http://dx.doi.org/10.1371/journal.pone.0027824
39. Devito, C., B. Zuber, U. Schröder, R. Benthin, K. Okuda, K. Broliden, B. Wahren, J. Hinkula. 2004. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol. 173:7078-7089.
40. Dhillon, A.K., H. Donners, R. Pantophlet, W.E. Johnson, J.M. Decker, G.M. Shaw, F.H. Lee, D.D. Richman, R.W. Doms, G. Vanham, D.R. Burton. 2007. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81:6548-6562. http://dx.doi.org/10.1128/JVI.02749-06
41. Dimitrov, J.D., M.D. Kazatchkine, S.V. Kaveri, S. Lacroix-Desmazes. 2011. "Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies. PLoS Pathog. 7:e1002095. http://dx.doi.org/10.1371/journal.ppat.1002095
42. Diskin, R., J.F. Scheid, P.M. Marcovecchio, A.P. West Jr., F. Klein, H. Gao, P.N. Gnanapragasam, A. Abadir, M.S. Seaman, M.C. Nussenzweig, P.J. Bjorkman. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 334:1289-1293. http://dx.doi.org/10.1126/science.1213782
43. Dong, M., P.F. Zhang, F. Grieder, J. Lee, G. Krishnamurthy, T. VanCott, C. Broder, V.R. Polonis, X.F. Yu, Y. Shao, et al. 2003. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J. Virol. 77:3119-3130. http://dx.doi.org/10.1128/JVI.77.5.3119-3130.2003
44. Doria-Rose, N.A., M.K. Louder, Z. Yang, S. O'Dell, M. Nason, S.D. Schmidt, K. McKee, M.S. Seaman, R.T. Bailer, J.R. Mascola. 2012. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J. Virol. 86:3393-3397. http://dx.doi.org/10.1128/JVI.06745-11
45. Douagi, I., M.N. Forsell, C. Sundling, S. O'Dell, Y. Feng, P. Dosenovic, Y. Li, R. Seder, K. Loré, J.R. Mascola, et al. 2010. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. J. Virol. 84:1683-1695. http://dx.doi.org/10.1128/JVI.01896-09
46. Durda, P.J., B. Leece, A. Jenoski, H. Rabin, A. Fisher, F. Wong-Staal. 1988. Characterization of murine monoclonal antibodies to HIV-1 induced by synthetic peptides. AIDS Res. Hum. Retroviruses. 4:331-342. http://dx.doi.org/10.1089/aid.1988.4.331
47. Earl, P.L., M. Robert-Guroff, T.J. Matthews, K. Krohn, W.T. London, B. Moss. 1989. Isolate- and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques. AIDS Res. Hum. Retroviruses. 5:23-32. http://dx.doi.org/10.1089/aid.1989.5.23
48. Falkowska, E., A. Ramos, Y. Feng, T. Zhou, S. Moquin, L.M. Walker, X. Wu, M.S. Seaman, T. Wrin, P.D. Kwong, et al. 2012. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 86:4394-4403. http://dx.doi.org/10.1128/JVI.06973-11
49. Ferrantelli, F., M.T. Maggiorella, I. Schiavoni, L. Sernicola, E. Olivieri, S. Farcomeni, M.R. Pavone-Cossut, S. Moretti, R. Belli, B. Collacchi, et al. 2011. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Vaccine. 29:2918-2932. http://dx.doi.org/10.1016/j.vaccine.2011.02.006
50. Flynn, N.M., D.N. Forthal, C.D. Harro, F.N. Judson, K.H. Mayer, M.F. Para rgp120 HIV Vaccine Study Group. 2005. Placebocontrolled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-665. http://dx.doi.org/10.1086/428404
51. Forsell, M.N., Y. Li, M. Sundbäck, K. Svehla, P. Liljeström, J.R. Mascola, R. Wyatt, G.B. Karlsson Hedestam. 2005. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J. Virol. 79:10902- 10914. http://dx.doi.org/10.1128/JVI.79.17.10902-10914.2005
52. Forsell, M.N., W.R. Schief, R.T. Wyatt. 2009. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS. 4:380- 387. http://dx.doi.org/10.1097/COH.0b013e32832edc19
53. Forsman, A., E. Beirnaert, M.M. Aasa-Chapman, B. Hoorelbeke, K. Hijazi, W. Koh, V. Tack, A. Szynol, C. Kelly, A. McKnight, et al. 2008. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J. Virol. 82:12069-12081. http://dx.doi.org/10.1128/JVI.01379-08
54. Forthal, D.N., C. Moog. 2009. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS. 4:388-393. http://dx.doi.org/10.1097/COH.0b013e32832f0a89
55. Gilbert, P., M. Wang, T. Wrin, C. Petropoulos, M. Gurwith, F. Sinangil, P. D'Souza, I.R. Rodriguez-Chavez, A. DeCamp, M. Giganti, et al. 2010. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202:595-605. http://dx.doi.org/10.1086/654816
56. Gorlani, A., J. Brouwers, C. McConville, P. van der Bijl, K. Malcolm, P. Augustijns, A.F. Quigley, R. Weiss, H. De Haard, T. Verrips. 2012. Llama antibody fragments have good potential for application as HIV type 1 topical microbicides. AIDS Res. Hum. Retroviruses. 28:198-205. http://dx.doi.org/10.1089/aid.2011.0133
57. Gorse, G.J., M.J. McElrath, T.J. Matthews, R.H. Hsieh, R.B. Belshe, L. Corey, S.E. Frey, D.J. Kennedy, M.C. Walker, M.M. Eibl National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 1998. Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. Vaccine. 16:493-506. http://dx.doi.org/10.1016/S0264-410X(97)80003-5
58. Graham, B.S., M.C. Keefer, M.J. McElrath, G.J. Gorse, D.H. Schwartz, K. Weinhold, T.J. Matthews, J.R. Esterlitz, F. Sinangil, P.E. Fast NIAID AIDS Vaccine Evaluation Group. 1996. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann. Intern. Med. 125:270-279.
59. Gray, E.S., M.C. Madiga, T. Hermanus, P.L. Moore, C.K. Wibmer, N.L. Tumba, L. Werner, K. Mlisana, S. Sibeko, C. Williamson, et al and the CAPRISA002 Study Team. 2011. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840. http://dx.doi.org/10.1128/JVI.00198-11
60. Haigwood, N.L., J.R. Shuster, G.K. Moore, H. Lee, P.V. Skiles, K.W. Higgins, P.J. Barr, C. George-Nascimento, K.S. Steimer. 1990. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses. 6:855- 869. http://dx.doi.org/10.1089/aid.1990.6.855
61. Hammonds, J., X. Chen, T. Fouts, A. DeVico, D. Montefiori, P. Spearman. 2005. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J. Virol. 79:14804-14814. http://dx.doi.org/10.1128/JVI.79.23.14804-14814.2005
62. Haynes, B.F., P.B. Gilbert, M.J. McElrath, S. Zolla-Pazner, G.D. Tomaras, S.M. Alam, D.T. Evans, D.C. Montefiori, C. Karnasuta, R. Sutthent, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286. http://dx.doi.org/10.1056/NEJMoa1113425
63. Hessell, A.J., N.L. Haigwood. 2012. Neutralizing antibodies and control of HIV: moves and countermoves. Curr. HIV/AIDS Rep. 9:64-72. http://dx.doi.org/10.1007/s11904-011-0105-5
64. Hessell, A.J., E.G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D.N. Forthal, W.C. Koff, D.I. Watkins, D.R. Burton. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433. http://dx.doi.org/10.1371/journal.ppat.1000433
65. Ho, D.D., J.C. Kaplan, I.E. Rackauskas, M.E. Gurney. 1988. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science. 239:1021-1023. http://dx.doi.org/10.1126/science.2830667
66. Huang, J., G. Ofek, L. Laub, M.K. Louder, N.A. Doria-Rose, N.S. Longo, H. Imamichi, R.T. Bailer, B. Chakrabarti, S.K. Sharma, et al. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 491:406-412. http://dx.doi.org/10.1038/nature11544
67. Jain, S., K.L. Rosenthal. 2011. The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis. Mucosal Immunol. 4:539-553. http://dx.doi.org/10.1038/mi.2011.21
68. Johnson, P.R., B.C. Schnepp, J. Zhang, M.J. Connell, S.M. Greene, E. Yuste, R.C. Desrosiers, K.R. Clark. 2009. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15:901-906. http://dx.doi.org/10.1038/nm.1967
69. Joyce, J.G., I.J. Krauss, H.C. Song, D.W. Opalka, K.M. Grimm, D.D. Nahas, M.T. Esser, R. Hrin, M. Feng, V.Y. Dudkin, et al. 2008. An oligosaccharidebased HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. Proc. Natl. Acad. Sci. USA. 105:15684-15689. http://dx.doi.org/10.1073/pnas.0807837105
70. Kim, M., Z.S. Qiao, D.C. Montefiori, B.F. Haynes, E.L. Reinherz, H.X. Liao. 2005. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res. Hum. Retroviruses. 21:58-67. http://dx.doi.org/10.1089/aid.2005.21.58
71. Klasse, P.J., R.W. Sanders, A. Cerutti, J.P. Moore. 2012. How can HIV-type-1-Env immunogenicity be improved to facilitate antibodybased vaccine development? AIDS Res. Hum. Retroviruses. 28:1-15. http://dx.doi.org/10.1089/aid.2011.0053
72. Klein, F., C. Gaebler, H. Mouquet, D.N. Sather, C. Lehmann, J.F. Scheid, Z. Kraft, Y. Liu, J. Pietzsch, A. Hurley, et al. 2012a. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 209:1469-1479. http://dx.doi.org/10.1084/jem.20120423
73. Klein, F., A. Halper-Stromberg, J.A. Horwitz, H. Gruell, J.F. Scheid, S. Bournazos, H. Mouquet, L.A. Spatz, R. Diskin, A. Abadir, et al. 2012b. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 492:118-122.
74. Kovacs, J.M., J.P. Nkolola, H. Peng, A. Cheung, J. Perry, C.A. Miller, M.S. Seaman, D.H. Barouch, B. Chen. 2012. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc. Natl. Acad. Sci. USA. 109:12111-12116. http://dx.doi.org/10.1073/pnas.1204533109
75. Kwong, P.D., J.R. Mascola, G.J. Nabel. 2012. The changing face of HIV vaccine research. J. Int. AIDS Soc. 15:17407.
76. Labrijn, A.F., P. Poignard, A. Raja, M.B. Zwick, K. Delgado, M. Franti, J. Binley, V. Vivona, C. Grundner, C.C. Huang, et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77:10557-10565. http://dx.doi.org/10.1128/JVI.77.19.10557-10565.2003
77. Lagenaur, L.A., V.A. Villarroel, V. Bundoc, B. Dey, E.A. Berger. 2010. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology. 7:11. http://dx.doi.org/10.1186/1742-4690-7-11
78. Lai, R.P., M.S. Seaman, P. Tonks, F. Wegmann, D.J. Seilly, S.D. Frost, C.C. LaBranche, D.C. Montefiori, A.K. Dey, I.K. Srivastava, et al. 2012. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. PLoS ONE. 7:e35083. http://dx.doi.org/10.1371/journal.pone.0035083
79. Lakhashe, S.K., V. Velu, G. Sciaranghella, N.B. Siddappa, J.M. Dipasquale, G. Hemashettar, J.K. Yoon, R.A. Rasmussen, F. Yang, S.J. Lee, et al. 2011. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine. 29:5611-5622. http://dx.doi.org/10.1016/j.vaccine.2011.06.017
80. Law, M., R.M. Cardoso, I.A. Wilson, D.R. Burton. 2007. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol. 81:4272-4285. http://dx.doi.org/10.1128/JVI.02536-06
81. Lewis, A.D., R. Chen, D.C. Montefiori, P.R. Johnson, K.R. Clark. 2002. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J. Virol. 76:8769-8775. http://dx.doi.org/10.1128/JVI.76.17.8769-8775.2002
82. Li, Y., B. Cleveland, I. Klots, B. Travis, B.A. Richardson, D. Anderson, D. Montefiori, P. Polacino, S.L. Hu. 2008. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 82: 638-651. http://dx.doi.org/10.1128/JVI.01691-07
83. Li, Y., S. O'Dell, L.M. Walker, X. Wu, J. Guenaga, Y. Feng, S.D. Schmidt, K. McKee, M.K. Louder, J.E. Ledgerwood, et al. 2011. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85:8954-8967. http://dx.doi.org/10.1128/JVI.00754-11
84. Lian, Y., I. Srivastava, V.R. Gómez-Román, J. Zur Megede, Y. Sun, E. Kan, S. Hilt, S. Engelbrecht, S. Himathongkham, P.A. Luciw, et al. 2005. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J. Virol. 79:13338- 13349. http://dx.doi.org/10.1128/JVI.79.21.13338-13349.2005
85. Lorin, C., L. Mollet, F. Delebecque, C. Combredet, B. Hurtrel, P. Charneau, M. Brahic, F. Tangy. 2004. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 78:146-157. http://dx.doi.org/10.1128/JVI.78.1.146-157.2004
86. Lubeck, M.D., R. Natuk, M. Myagkikh, N. Kalyan, K. Aldrich, F. Sinangil, S. Alipanah, S.C. Murthy, P.K. Chanda, S.M. Nigida Jr., et al. 1997. Longterm protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3:651-658. http://dx.doi.org/10.1038/nm0697-651
87. Lynch, R.M., L. Tran, M.K. Louder, S.D. Schmidt, M. Cohen, R. Dersimonian, Z. Euler, E.S. Gray, S. Abdool Karim, J. Kirchherr, et al; CHAVI 001 Clinical Team Members. 2012. The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 86:7588-7595. http://dx.doi.org/10.1128/JVI.00734-12
88. Ma, B.J., S.M. Alam, E.P. Go, X. Lu, H. Desaire, G.D. Tomaras, C. Bowman, L.L. Sutherland, R.M. Scearce, S. Santra, et al. 2011. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog. 7:e1002200. http://dx.doi.org/10.1371/journal.ppat.1002200
89. Malherbe, D.C., N.A. Doria-Rose, L. Misher, T. Beckett, W.B. Puryear, J.T. Schuman, Z. Kraft, J. O'Malley, M. Mori, I. Srivastava, et al. 2011. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J. Virol. 85:5262-5274. http://dx.doi.org/10.1128/JVI.02419-10
90. Mascola, J.R., S.W. Snyder, O.S. Weislow, S.M. Belay, R.B. Belshe, D.H. Schwartz, M.L. Clements, R. Dolin, B.S. Graham, G.J. Gorse, et al; The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348. http://dx.doi.org/10.1093/infdis/173.2.340
91. Mascola, J.R., M.G. Lewis, G. Stiegler, D. Harris, T.C. VanCott, D. Hayes, M.K. Louder, C.R. Brown, C.V. Sapan, S.S. Frankel, et al. 1999. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
92. Mascola, J.R., G. Stiegler, T.C. VanCott, H. Katinger, C.B. Carpenter, C.E. Hanson, H. Beary, D. Hayes, S.S. Frankel, D.L. Birx, M.G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210. http://dx.doi.org/10.1038/72318
93. Mascola, J.R., A. Sambor, K. Beaudry, S. Santra, B. Welcher, M.K. Louder, T.C. Vancott, Y. Huang, B.K. Chakrabarti, W.P. Kong, et al. 2005. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. 79:771-779. http://dx.doi.org/10.1128/JVI.79.2.771-779.2005
94. McBurney, S.P., K.R. Young, T.M. Ross. 2007. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology. 358:334-346. http://dx.doi.org/10.1016/j.virol.2006.08.032
95. McCoy, L.E., A.F. Quigley, N.M. Strokappe, B. Bulmer-Thomas, M.S. Seaman, D. Mortier, L. Rutten, N. Chander, C.J. Edwards, R. Ketteler, et al. 2012. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 209:1091-1103. http://dx.doi.org/10.1084/jem.20112655
96. McElrath, M.J., B.F. Haynes. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 33:542-554. http://dx.doi.org/10.1016/j.immuni.2010.09.011
97. McLellan, J.S., M. Pancera, C. Carrico, J. Gorman, J.P. Julien, R. Khayat, R. Louder, R. Pejchal, M. Sastry, K. Dai, et al. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 480:336-343. http://dx.doi.org/10.1038/nature10696
98. McMichael, A.J., B.F. Haynes. 2012. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat. Immunol. 13:423-427. http://dx.doi.org/10.1038/ni.2264
99. Mehandru, S., T. Wrin, J. Galovich, G. Stiegler, B. Vcelar, A. Hurley, C. Hogan, S. Vasan, H. Katinger, C.J. Petropoulos, M. Markowitz. 2004. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, 4E10. J. Virol. 78:14039- 14042. http://dx.doi.org/10.1128/JVI.78.24.14039-14042.2004
100. Moir, S., A. Malaspina, A.S. Fauci. 2011. Prospects for an HIV vaccine: leading B cells down the right path. Nat. Struct. Mol. Biol. 18:1317- 1321. http://dx.doi.org/10.1038/nsmb.2194
101. Moldt, B., M. Shibata-Koyama, E.G. Rakasz, N. Schultz, Y. Kanda, D.C. Dunlop, S.L. Finstad, C. Jin, G. Landucci, M.D. Alpert, et al. 2012. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced Fc?RIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86:6189-6196. http://dx.doi.org/10.1128/JVI.00491-12
102. Montefiori, D.C., C. Karnasuta, Y. Huang, H. Ahmed, P. Gilbert, M.S. de Souza, R. McLinden, S. Tovanabutra, A. Laurence-Chenine, E. Sanders-Buell, et al. 2012. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206:431-441. http://dx.doi.org/10.1093/infdis/jis367
103. Mörner, A., I. Douagi, M.N. Forsell, C. Sundling, P. Dosenovic, S. O'Dell, B. Dey, P.D. Kwong, G. Voss, R. Thorstensson, et al. 2009. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J. Virol. 83:540-551. http://dx.doi.org/10.1128/JVI.01102-08
104. Moulard, M., S.K. Phogat, Y. Shu, A.F. Labrijn, X. Xiao, J.M. Binley, M.Y. Zhang, I.A. Sidorov, C.C. Broder, J. Robinson, et al. 2002. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. USA. 99:6913-6918. http://dx.doi.org/10.1073/pnas.102562599
105. Murphy, K. 2011. The distribution and functions of immunoglobulin isotypes. In Janeway's Immunobiology. 8th edition. Garland Science, New York. 408-417.
106. Nara, P.L., W.G. Robey, S.W. Pyle, W.C. Hatch, N.M. Dunlop, J.W. Bess Jr., J.C. Kelliher, L.O. Arthur, P.J. Fischinger. 1988. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J. Virol. 62:2622-2628.
107. Ndung'u, T., R.A. Weiss. 2012. On HIV diversity. AIDS. 26:1255- 1260. http://dx.doi.org/10.1097/QAD.0b013e32835461b5
108. Nelson, J.D., H. Kinkead, F.M. Brunel, D. Leaman, R. Jensen, J.M. Louis, T. Maruyama, C.A. Bewley, K. Bowdish, G.M. Clore, et al. 2008. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology. 377:170-183. http://dx.doi.org/10.1016/j.virol.2008.04.005
109. Nishimura, Y., T. Igarashi, N.L. Haigwood, R. Sadjadpour, O.K. Donau, C. Buckler, R.J. Plishka, A. Buckler-White, M.A. Martin. 2003. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. USA. 100:15131-15136. http://dx.doi.org/10.1073/pnas.2436476100
110. Nishiyama, Y., S. Planque, Y. Mitsuda, G. Nitti, H. Taguchi, L. Jin, J. Symersky, S. Boivin, M. Sienczyk, M. Salas, et al. 2009. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J. Biol. Chem. 284:30627-30642. http://dx.doi.org/10.1074/jbc.M109.032185
111. Pantaleo, G., M. Esteban, B. Jacobs, J. Tartaglia. 2010. Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS. 5:391-396. http://dx.doi.org/10.1097/COH.0b013e32833d1e87
112. Parren, P.W., P.A. Marx, A.J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J.P. Moore, D.R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347. http://dx.doi.org/10.1128/JVI.75.17.8340-8347.2001
113. Pejchal, R., I.A. Wilson. 2010. Structure-based vaccine design in HIV: blind men and the elephant? Curr. Pharm. Des. 16:3744-3753. http://dx.doi.org/10.2174/138161210794079173
114. Pejchal, R., K.J. Doores, L.M. Walker, R. Khayat, P.S. Huang, S.K. Wang, R.L. Stanfield, J.P. Julien, A. Ramos, M. Crispin, et al. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 334:1097-1103. http://dx.doi.org/10.1126/science.1213256
115. Picker, L.J., S.G. Hansen, J.D. Lifson. 2012. New paradigms for HIV/AIDS vaccine development. Annu. Rev. Med. 63:95-111. http://dx.doi.org/10.1146/annurev-med-042010-085643
116. Pincus, S.H., K.G. Messer, R. Cole, R. Ireland, T.C. VanCott, A. Pinter, D.H. Schwartz, B.S. Graham, G.J. Gorse. 1997. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J. Immunol. 158:3511-3520.
117. Pitisuttithum, P., P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J.W. Tappero, K. Choopanya Bangkok Vaccine Evaluation Group. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194: 1661-1671. http://dx.doi.org/10.1086/508748
118. Plotkin, S.A. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47:401-409. http://dx.doi.org/10.1086/589862
119. Poignard, P., R. Sabbe, G.R. Picchio, M. Wang, R.J. Gulizia, H. Katinger, P.W. Parren, D.E. Mosier, D.R. Burton. 1999. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 10:431-438. http://dx.doi.org/10.1016/S1074-7613(00)80043-6
120. Poon, B., J.F. Hsu, V. Gudeman, I.S. Chen, K. Grovit-Ferbas. 2005. Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses. J. Virol. 79:10210-10217. http://dx.doi.org/10.1128/JVI.79.16.10210-10217.2005
121. Quinnan, G.V. Jr., X.F. Yu, M.G. Lewis, P.F. Zhang, G. Sutter, P. Silvera, M. Dong, A. Choudhary, P.T. Sarkis, P. Bouma, et al. 2005. Protection of rhesus monkeys against infection with minimally pathogenic simianhuman immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J. Virol. 79:3358-3369. http://dx.doi.org/10.1128/JVI.79.6.3358-3369.2005
122. Radaelli, A., O. Bonduelle, P. Beggio, B. Mahe, E. Pozzi, V. Elli, M. Paganini, C. Zanotto, C. De Giuli Morghen, B. Combadière. 2007. Primeboost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine. 25:2128-2138. http://dx.doi.org/10.1016/j.vaccine.2006.11.009
123. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al MOPHTAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220. http://dx.doi.org/10.1056/NEJMoa0908492
124. Robert-Guroff, M., M. Brown, R.C. Gallo. 1985. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature. 316:72-74. http://dx.doi.org/10.1038/316072a0
125. Robey, W.G., L.O. Arthur, T.J. Matthews, A. Langlois, T.D. Copeland, N.W. Lerche, S. Oroszlan, D.P. Bolognesi, R.V. Gilden, P.J. Fischinger. 1986. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc. Natl. Acad. Sci. USA. 83:7023-7027. http://dx.doi.org/10.1073/pnas.83.18.7023
126. Rollman, E., J. Hinkula, J. Arteaga, B. Zuber, A. Kjerrström, M. Liu, B. Wahren, K. Ljungberg. 2004. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther. 11:1146-1154. http://dx.doi.org/10.1038/sj.gt.3302275
127. Rosen, O., J. Chill, M. Sharon, N. Kessler, B. Mester, S. Zolla-Pazner, J. Anglister. 2005. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry. 44:7250-7258. http://dx.doi.org/10.1021/bi047387t
128. Russell, N.D., B.S. Graham, M.C. Keefer, M.J. McElrath, S.G. Self, K.J. Weinhold, D.C. Montefiori, G. Ferrari, H. Horton, G.D. Tomaras, et al National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. 2007. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J. Acquir. Immune Defic. Syndr. 44:203-212. http://dx.doi.org/10.1097/01.qai.0000248356.48501.ff
129. Sattentau, Q.J. 2011. Vaccinology: A sweet cleft in HIV's armour. Nature. 480:324-325. http://dx.doi.org/10.1038/480324a
130. Scheid, J.F., H. Mouquet, N. Feldhahn, M.S. Seaman, K. Velinzon, J. Pietzsch, R.G. Ott, R.M. Anthony, H. Zebroski, A. Hurley, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIVinfected individuals. Nature. 458:636-640. http://dx.doi.org/10.1038/nature07930
131. Scheid, J.F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 333:1633-1637. http://dx.doi.org/10.1126/science.1207227
132. Schell, J., N.F. Rose, N. Fazo, P.A. Marx, M. Hunter, E. Ramsburg, D. Montefiori, P. Earl, B. Moss, J.K. Rose. 2009. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine. 27:979-986. http://dx.doi.org/10.1016/j.vaccine.2008.12.017
133. Sheppard, N., Q. Sattentau. 2005. The prospects for vaccines against HIV-1: more than a field of long-term nonprogression? Expert Rev. Mol. Med. 7:1-21. http://dx.doi.org/10.1017/S1462399405008859
134. Shibata, R., T. Igarashi, N. Haigwood, A. Buckler-White, R. Ogert, W. Ross, R. Willey, M.W. Cho, M.A. Martin. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:204-210. http://dx.doi.org/10.1038/5568
135. Simek, M.D., W. Rida, F.H. Priddy, P. Pung, E. Carrow, D.S. Laufer, J.K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348. http://dx.doi.org/10.1128/JVI.00110-09
136. Sreepian, A., J. Permmongkol, W. Kantakamalakul, S. Siritantikorn, N. Tanlieng, R. Sutthent. 2009. HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses. J. Immune Based Ther. Vaccines. 7:5. http://dx.doi.org/10.1186/1476-8518-7-5
137. Stanfield, R.L., M.K. Gorny, C. Williams, S. Zolla-Pazner, I.A. Wilson. 2004. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure. 12:193-204.
138. Stiegler, G., R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, H. Katinger. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 17:1757-1765. http://dx.doi.org/10.1089/08892220152741450
139. Strokappe, N., A. Szynol, M. Aasa-Chapman, A. Gorlani, A. Forsman Quigley, D.L. Hulsik, L. Chen, R. Weiss, H. de Haard, T. Verrips. 2012. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS ONE. 7:e33298. http://dx.doi.org/10.1371/journal.pone.0033298
140. Sundling, C., M.N. Forsell, S. O'Dell, Y. Feng, B. Chakrabarti, S.S. Rao, K. Loré, J.R. Mascola, R.T. Wyatt, I. Douagi, G.B. Karlsson Hedestam. 2010. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J. Exp. Med. 207:2003-2017. http://dx.doi.org/10.1084/jem.20100025
141. Tiller, T., E. Meffre, S. Yurasov, M. Tsuiji, M.C. Nussenzweig, H. Wardemann. 2008. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods. 329:112-124. http://dx.doi.org/10.1016/j.jim.2007.09.017
142. Traina-Dorge, V., B. Pahar, P. Marx, P. Kissinger, D. Montefiori, Y. Ou, W.L. Gray. 2010. Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. Vaccine. 28:6483-6490. http://dx.doi.org/10.1016/j.vaccine.2010.07.018
143. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J.P. Moore, H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
144. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622. http://dx.doi.org/10.1038/nm1244
145. Tudor, D., M. Derrien, L. Diomede, A.S. Drillet, M. Houimel, C. Moog, J.M. Reynes, L. Lopalco, M. Bomsel. 2009. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2:412-426. http://dx.doi.org/10.1038/mi.2009.89
146. Vaine, M., S. Wang, Q. Liu, J. Arthos, D. Montefiori, P. Goepfert, M.J. McElrath, S. Lu. 2010. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Envspecific antibodies. PLoS ONE. 5:e13916. http://dx.doi.org/10.1371/journal.pone.0013916
147. VanCott, T.C., J.R. Mascola, R.W. Kaminski, V. Kalyanaraman, P.L. Hallberg, P.R. Burnett, J.T. Ulrich, D.J. Rechtman, D.L. Birx. 1997. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:4319-4330.
148. Veazey, R.S., R.J. Shattock, M. Pope, J.C. Kirijan, J. Jones, Q. Hu, T. Ketas, P.A. Marx, P.J. Klasse, D.R. Burton, J.P. Moore. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:343-346. http://dx.doi.org/10.1038/nm833
149. Verkoczy, L., G. Kelsoe, M.A. Moody, B.F. Haynes. 2011. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 23:383-390. http://dx.doi.org/10.1016/j.coi.2011.04.003
150. Verrier, F., S. Burda, R. Belshe, A.M. Duliege, J.L. Excler, M. Klein, S. Zolla-Pazner. 2000. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, dualtropic clade B and C primary isolates. J. Virol. 74:10025-10033. http://dx.doi.org/10.1128/JVI.74.21.10025-10033.2000
151. Walker, L.M., D.R. Burton. 2010. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22:358-366. http://dx.doi.org/10.1016/j.coi.2010.02.012
152. Walker, L.M., S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, et al Protocol G Principal Investigators. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326:285-289. http://dx.doi.org/10.1126/science.1178746
153. Walker, L.M., M. Huber, K.J. Doores, E. Falkowska, R. Pejchal, J.P. Julien, S.K. Wang, A. Ramos, P.Y. Chan-Hui, M. Moyle, et al Protocol G Principal Investigators. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 477:466-470. http://dx.doi.org/10.1038/nature10373
154. Watkins, J.D., N.B. Siddappa, S.K. Lakhashe, M. Humbert, A. Sholukh, G. Hemashettar, Y.L. Wong, J.K. Yoon, W. Wang, F.J. Novembre, et al. 2011. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS ONE. 6:e18207. http://dx.doi.org/10.1371/journal.pone.0018207
155. Weiss, R.A., P.R. Clapham, R. Cheingsong-Popov, A.G. Dalgleish, C.A. Carne, I.V. Weller, R.S. Tedder. 1985. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 316:69-72. http://dx.doi.org/10.1038/316069a0
156. Weiss, R.A., P.R. Clapham, J.N. Weber, A.G. Dalgleish, L.A. Lasky, P.W. Berman. 1986. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 324:572-575. http://dx.doi.org/10.1038/324572a0
157. West, A.P. Jr., R. Diskin, M.C. Nussenzweig, P.J. Bjorkman. 2012. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA. 109:E2083-E2090. http://dx.doi.org/10.1073/pnas.1208984109
158. Willey, S., M.M. Aasa-Chapman. 2008. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol. 16:596- 604. http://dx.doi.org/10.1016/j.tim.2008.08.008
159. Wilson, C., M.S. Reitz Jr., K. Aldrich, P.J. Klasse, J. Blomberg, R.C. Gallo, M. Robert-Guroff. 1990. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J. Virol. 64:3240-3248.
160. Wright, P.F., J. Mestecky, M.J. McElrath, M.C. Keefer, G.J. Gorse, P.A. Goepfert, Z. Moldoveanu, D. Schwartz, P.W. Spearman, R. El Habib, et al National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 2004. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J. Infect. Dis. 189:1221-1231. http://dx.doi.org/10.1086/382088
161. Wrin, T., J.H. Nunberg. 1994. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals. AIDS. 8:1622-1623. http://dx.doi.org/10.1097/00002030-199411000-00017
162. Wrin, T., T.P. Loh, J.C. Vennari, H. Schuitemaker, J.H. Nunberg. 1995. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69:39-48.
163. Wu, X., Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 329:856-861. http://dx.doi.org/10.1126/science.1187659
164. Yang, X., J. Lee, E.M. Mahony, P.D. Kwong, R. Wyatt, J. Sodroski. 2002. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76:4634-4642. http://dx.doi.org/10.1128/JVI.76.9.4634-4642.2002
165. Zhang, P.F., F. Cham, M. Dong, A. Choudhary, P. Bouma, Z. Zhang, Y. Shao, Y.R. Feng, L. Wang, N. Mathy, et al. 2007. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl. Acad. Sci. USA. 104:10193-10198. http://dx.doi.org/10.1073/pnas.0608635104
166. Zhou, T., I. Georgiev, X. Wu, Z.Y. Yang, K. Dai, A. Finzi, Y.D. Kwon, J.F. Scheid, W. Shi, L. Xu, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 329:811-817. http://dx.doi.org/10.1126/science.1192819
167. Zhou, M., I. Kostoula, B. Brill, E. Panou, M. Sakarellos-Daitsiotis, U. Dietrich. 2012. Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice. Vaccine. 30:1911-1916. http://dx.doi.org/10.1016/j.vaccine.2012.01.026
168. Zolla-Pazner, S., M. Lubeck, S. Xu, S. Burda, R.J. Natuk, F. Sinangil, K. Steimer, R.C. Gallo, J.W. Eichberg, T. Matthews, M. Robert-Guroff. 1998a. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J. Virol. 72:1052-1059.
169. Zolla-Pazner, S., S. Xu, S. Burda, A.M. Duliege, J.L. Excler, M.L. Clements-Mann. 1998b. Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines. J. Infect. Dis. 178:1502-1506. http://dx.doi.org/10.1086/314452